IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics

Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing

Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482

Linear Models and Empirical Bayes Methods for Assessing Differential Expression in Microarray Experiments

Smyth, G. K. (2004) · Statistical Applications in Genetics and Molecular Biology · doi:10.2202/1544-6115.1027 · Cited by 11,829

The control of the false discovery rate in multiple testing under dependency

Benjamini, Y., & Yekutieli, D. (2001) · The Annals of Statistics · doi:10.1214/aos/1013699998 · Cited by 10,490

Statistical significance for genomewide studies

Storey, J. D., & Tibshirani, R. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1530509100 · Cited by 9,692

An Integrated Genomic Analysis of Human Glioblastoma Multiforme

Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857

Bismark: a flexible aligner and methylation caller for Bisulfite-Seq applications

Krueger, F., & Andrews, S. (2011) · Bioinformatics · doi:10.1093/bioinformatics/btr167 · Cited by 5,275

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., et al. (2009) · Nature · doi:10.1038/nature08617 · Cited by 4,154

Oncometabolite 2-Hydroxyglutarate Is a Competitive Inhibitor of α-Ketoglutarate-Dependent Dioxygenases

Xu, W., Yang, H., Liu, Y., Yang, Y., Wang, P., Kim, S.-H., Ito, S., Yang, C., Wang, P., Xiao, M.-T., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.12.014 · Cited by 2,875

Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation

Figueroa, M. E., Abdel-Wahab, O., Lu, C., Ward, P. S., Patel, J., Shih, A., Li, Y., Bhagwat, N., Vasanthakumar, A., Fernandez, H. F., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.11.015 · Cited by 2,766

Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma

Noushmehr, H., Weisenberger, D. J., Diefes, K., Phillips, H. S., Pujara, K., Berman, B. P., Pan, F., Pelloski, C. E., Sulman, E. P., Bhat, K. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.03.017 · Cited by 2,337

Metabolic shift in density-dependent stem cell differentiation

Singh, S. J., Turner, W. S., Glaser, D. E., McCloskey, K. E., & Filipp, F. V. (2017) · Cell Communication and Signaling · doi:10.1186/s12964-017-0173-2 · Cited by 23

In vivo efficacy of mutant IDH1 inhibitor HMS-101 and structural resolution of distinct binding site

Chaturvedi, A., Goparaju, R., Gupta, C., Weder, J., Klünemann, T., Cruz, M. M. A., Kloos, A., Görlich, K., Schottmann, R., Othman, B., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0582-x · Cited by 25

Illuminating the cross-talk between tumor metabolism and immunity in IDH-mutated cancers

Leca, J., Fortin, J., & Mak, T. W. (2020) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2020.11.013 · Cited by 23

Novel Antigen Targets for Immunotherapy of Acute Myeloid Leukemia

Goswami, M., & Hourigan, C. S. (2015) · Current Drug Targets · doi:10.2174/1389450116666150223120005 · Cited by 23

Disabling Uncompetitive Inhibition of Oncogenic IDH Mutations Drives Acquired Resistance

Lyu, J., Liu, Y., Gong, L., Chen, M., Madanat, Y. F., Zhang, Y., Cai, F., Gu, Z., Cao, H., Kaphle, P., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1661 · Cited by 23

Oncogenic Drivers in Myeloproliferative Neoplasms: From JAK2 to Calreticulin Mutations

Cahu, X., & Constantinescu, S. N. (2015) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-015-0278-x · Cited by 22

Idh1 mutations contribute to the development of T-cell malignancies in genetically engineered mice

Hao, Z., Cairns, R. A., Inoue, S., Li, W. Y., Sheng, Y., Lemonnier, F., Wakeham, A. C., Snow, B. E., Dominguez‐Brauer, C., Ye, J., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1525354113 · Cited by 22

IDH1R132H Promotes Malignant Transformation of Benign Prostatic Epithelium by Dysregulating MicroRNAs: Involvement of IGF1R-AKT/STAT3 Signaling Pathway

Zhang, L., Qi, M., Feng, T., Hu, J., Wang, L., Li, X., Gao, W. Q., Liu, H., Jiao, M., Wu, Z., et al. (2018) · Neoplasia · doi:10.1016/j.neo.2017.12.001 · Cited by 21

IDH1/2 Mutations in Cancer Stem Cells and Their Implications for Differentiation Therapy

Molenaar, R. J., & Wilmink, J. W. (2021) · Journal of Histochemistry & Cytochemistry · doi:10.1369/00221554211062499 · Cited by 22

IDH1 -Mutant Preleukemic Hematopoietic Stem Cells Can Be Eliminated by Inhibition of Oxidative Phosphorylation

Landberg, N., Köhnke, T., Feng, Y., Nakauchi, Y., Fan, A. C., Linde, M. H., Karigane, D., Lim, K. S., Sinha, R., Malcovati, L., et al. (2023) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-23-0195 · Cited by 23

Genetically Modeled Mice with Mutations in Mitochondrial Metabolic Enzymes for the Study of Cancer

Piruat, J. I., & Millán‐Uclés, Á. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00200 · Cited by 21

Mitochondrial metabolic remodeling in response to genetic and environmental perturbations

Hollinshead, K. E. R., & Tennant, D. A. (2016) · WIREs Systems Biology and Medicine · doi:10.1002/wsbm.1334 · Cited by 22

Isocitrate dehydrogenase1 mutation reduces the pericyte coverage of microvessels in astrocytic tumours

Sun, C., Zhao, Y., Shi, J., Zhang, J., Yuan, Y., Gu, Y., Zhang, F., Gao, X., Wang, C., Wang, Y., et al. (2019) · Journal of Neuro-Oncology · doi:10.1007/s11060-019-03156-5 · Cited by 23

Isocitrate dehydrogenase 1 and 2 mutations in gliomas

Houdova, M. M., Drábek, J., Koudeláková, V., Trojanec, R., Kalita, O., & Hajdúch, M. (2014) · Journal of Neuroscience Research · doi:10.1002/jnr.23456 · Cited by 20

Releasing the Block: Setting Differentiation Free with Mutant IDH Inhibitors

Pirozzi, C. J., Reitman, Z. J., & Yan, H. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.04.024 · Cited by 20

Epigenetic deregulation in myeloid malignancies

Huang, H.-T., & Figueroa, M. E. (2021) · Blood · doi:10.1182/blood.2019004262 · Cited by 21

D-2-hydroxyglutarate dehydrogenase governs adult neural stem cell activation and promotes histone acetylation via ATP-citrate lyase

Liu, Y., Wang, M., Guo, Y., Wang, L., & Guo, W. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112067 · Cited by 21

Isocitrate dehydrogenase (IDH)2 R140Q mutation induces myeloid and lymphoid neoplasms in mice

Mylonas, E., Janin, M., Bawa, O., Opolon, P., David, M. D., Quivoron, C., Bernard, O., Ottolenghi, C., Debotton, S., & Penard‐Lacronique, V. (2014) · Leukemia · doi:10.1038/leu.2014.18 · Cited by 20

Complex role of HIF in cancer: the known, the unknown, and the unexpected

Huang, E. L., Tiburcio, P. D. B., & Choi, H. (2014) · Hypoxia · doi:10.2147/hp.s50651 · Cited by 20

Epigenome modifiers and metabolic rewiring: New frontiers in therapeutics

Ferrari, A., Longo, R., Silva, R., Mitro, N., Caruso, D., De Fabiani, E., & Crestani, M. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.08.008 · Cited by 19

IDH1R132H Causes Resistance to HDAC Inhibitors by Increasing NANOG in Glioblastoma Cells

Kim, G., Choi, S. Y., Oh, T.-I., Kan, S.-Y., Kang, H., Lee, S., Oh, T., Ko, H. M., & Lim, J.-H. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20112679 · Cited by 19

Adult precision medicine: learning from the past to enhance the future

Ghiaseddin, A. P., Hoang-Minh, L., Janiszewska, M., Shin, D. H., Wick, W., Mitchell, D. A., Wen, P. Y., & Grossman, S. A. (2020) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdaa145 · Cited by 19

Mutant IDH regulates glycogen metabolism from early cartilage development to malignant chondrosarcoma formation

Pathmanapan, S., Poon, R. W. M., Renshaw, T. B. D., Nadesan, P., Nakagawa, M., Seesankar, G., Loe, A. K. H., Zhang, H. H., Guinovart, J. J., Durán, J., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112578 · Cited by 18

Targeted Differentiation Therapy with Mutant IDH Inhibitors: Early Experiences and Parallels with Other Differentiation Agents

Stein, E. M., & Yen, K. E. (2017) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-050216-122051 · Cited by 18

Fire and water: Tumor cell adaptation to metabolic conditions

Cairns, R. A., & Mak, T. W. (2017) · Experimental Cell Research · doi:10.1016/j.yexcr.2017.04.029 · Cited by 18

Abnormal folate metabolism causes age‐, sex‐ and parent‐of‐origin‐specific haematological defects in mice

Padmanabhan, N., Menelaou, K., Gao, J., Anderson, A. R. A., Blake, G. E. T., Li, T., Daw, B. N., & Watson, E. D. (2018) · The Journal of Physiology · doi:10.1113/jp276419 · Cited by 18

Evaluating ivosidenib for the treatment of relapsed/refractory AML: design, development, and place in therapy

Nassereddine, S., Lap, C. J. G., & Tabbara, I. A. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s182443 · Cited by 20

Metabolomics of Glioma

Feng, S., & Liu, Y. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-51652-9_18 · Cited by 18

Defining the landscape of metabolic dysregulations in cancer metastasis

Kader, S. A., Dib, S. S., Achkar, I. W., Thareja, G., Suhre, K., Rafii, A., & Halama, A. (2021) · Clinical & Experimental Metastasis · doi:10.1007/s10585-021-10140-9 · Cited by 18

Synergistic anti-tumor efficacy of mutant isocitrate dehydrogenase 1 inhibitor SYC-435 with standard therapy in patient-derived xenograft mouse models of glioma

Kogiso, M., Qi, L., Du, Y., Braun, F., Zhang, H., Huang, L. F., Guo, L., Huang, Y., Teo, W., Lindsay, H., et al. (2022) · Translational Oncology · doi:10.1016/j.tranon.2022.101368 · Cited by 17

Molecular biomarkers in pediatric glial tumors

Fontebasso, A. M., Béchet, D., & Jabado, N. (2013) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000007 · Cited by 17

Intracellular cholesterol biosynthesis in enchondroma and chondrosarcoma

Zhang, H., Wei, Q., Tsushima, H., Puviindran, V., Tang, Y. J., Pathmanapan, S., Poon, R. W. M., Ramu, E., Al‐Jazrawe, M., Wunder, J. S., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.127232 · Cited by 17

Mir142 loss unlocks IDH2R140-dependent leukemogenesis through antagonistic regulation of HOX genes

Marshall, A., Kasturiarachchi, J., Datta, P., Guo, Y.-P., Deltcheva, E., James, C., Brown, J., May, G., Anandagoda, N., Jackson, I., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-76218-8 · Cited by 11

Radiosynthesis and biological evaluation of [18F]AG-120 for PET imaging of the mutant isocitrate dehydrogenase 1 in glioma

Lai, T. H., Wenzel, B., Dukić-Stefanović, S., Teodoro, R., Arnaud, L., Maisonial‐Besset, A., Weber, V., Moldovan, R., Meister, S., Pietzsch, J., et al. (2023) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-023-06515-7 · Cited by 16

Isocitrate dehydrogenase 1 mutation sensitizes intrahepatic cholangiocarcinoma to the BET inhibitor JQ 1

Fujiwara, H., Tateishi, K., Kato, H., Nakatsuka, T., Yamamoto, K., Tanaka, Y., Ijichi, H., Takahara, N., Mizuno, S., Kogure, H., et al. (2018) · Cancer Science · doi:10.1111/cas.13784 · Cited by 16

Synthesis and biological evaluation of 3-aryl-4-indolyl-maleimides as potent mutant isocitrate dehydrogenase-1 inhibitors

Liu, X., Hu, Y., Gao, A., Xu, M., Gao, L., Xu, L., Zhou, Y., Gao, J., Ye, Q., & Li, J. X. (2018) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2018.12.029 · Cited by 16

TNFAIP8 drives metabolic reprogramming to promote prostate cancer cell proliferation

Niture, S. K., Lin, M., Odera, J. O., Moore, J. T., Zhe, H., Chen, X. L., Suy, S., Collins, S. P., & Kumar, D. (2020) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2020.105885 · Cited by 16

Transcriptional regulation of metabolism in disease: From transcription factors to epigenetics

Hawkins, L. J., Al-attar, R., & Storey, K. B. (2018) · PeerJ · doi:10.7717/peerj.5062 · Cited by 17

Isocitrate Dehydrogenase Mutations in Cancer: Mechanisms of Transformation and Metabolic LiabilityPreprint

Gunn, K., & Losman, J.-A. (2024) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041537 · Cited by 16

Deciphering the multifaceted roles and clinical implications of 2-hydroxyglutarate in cancer

Hao, J., Huang, Z., Zhang, S., Song, K., Wang, J., Gao, C., Fang, Z., & Zhang, N. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107437 · Cited by 15

Challenges for the development of mutant isocitrate dehydrogenases 1 inhibitors to treat glioma

Wang, Q.-X., Zhang, P.-Y., Li, Q., Tong, Z., Yu, S., Yu, Y., Yu, Y., Ding, N., Leng, X.-J., Chang, L., et al. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115464 · Cited by 15

Preleukemic single-cell landscapes reveal mutation-specific mechanisms and gene programs predictive of AML patient outcomes

Isobe, T., Kuciński, I., Barile, M., Wang, X., Hannah, R., Bastos, H. P., Chabra, S., Vijayabaskar, M. S., Sturgess, K., Williams, M., et al. (2023) · Cell Genomics · doi:10.1016/j.xgen.2023.100426 · Cited by 15

Recent Developments in Differentiation Therapy of Acute Myeloid Leukemia

Testa, U., Castelli, G., & Pelosi, E. (2025) · Cancers · doi:10.3390/cancers17071141 · Cited by 15

Metabolic alteration in tumorigenesis

Yang, H., Xiong, Y., & Guan, K. (2013) · Science China Life Sciences · doi:10.1007/s11427-013-4549-2 · Cited by 16

DNA Methylation and Intra-Clonal Heterogeneity: The Chronic Myeloid Leukemia Model

Lebecque, B., Bourgne, C., Vidal, V., & Berger, M. G. (2021) · Cancers · doi:10.3390/cancers13143587 · Cited by 15

Alternative Lengthening of Telomeres: Lessons to Be Learned from Telomeric DNA Double-Strand Break Repair

Kent, T., & Clynes, D. (2021) · Genes · doi:10.3390/genes12111734 · Cited by 16

New Insights in AML Biology From Genomic Analysis

Perry, A. M., & Attar, E. C. (2014) · Seminars in Hematology · doi:10.1053/j.seminhematol.2014.08.005 · Cited by 15

Immunoediting in acute myeloid leukemia: Reappraising T cell exhaustion and the aberrant antigen processing machinery in leukemogenesis

Wang, C., Lin, S.-C., Chang, K.-J., Cheong, H.-P., Wu, S.-R., Lee, C.-H., Chuang, M.-W., Chiou, S., Hsu, C., & Ko, P. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e39731 · Cited by 14

Mutation of IDH1 aggravates the fatty acid‑induced oxidative stress in HCT116 cells by affecting the mitochondrial respiratory chain

Li, S., Sun, C., Gu, Y., Gao, X., Zhao, Y., Yuan, Y., Zhang, F., Hu, P., Liang, W., Cao, K., et al. (2019) · Molecular Medicine Reports · doi:10.3892/mmr.2019.9903 · Cited by 14

IDH2 mutations in patients with normal karyotype AML predict favorable responses to daunorubicin, cytarabine and cladribine regimen

Libura, M. A., Białopiotrowicz, E., Giebel, S., Wierzbowska, A., Roboz, G. J., Piątkowska‐Jakubas, B., Pawełczyk, M., Górniak, P., Borg, K., Wojtas, M., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-88120-y · Cited by 14

Registered report: Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases

Evans, B., Griner, E., & Reproducibility Project: Cancer Biology (2015) · eLife · doi:10.7554/elife.07420 · Cited by 14

Nichtkanonische Basen im Genom: die regulative Informationsebene in der DNA

Carell, T., Kurz, M. Q., Müller, M., Rossa, M., & Spada, F. (2017) · Angewandte Chemie · doi:10.1002/ange.201708228 · Cited by 14

Molecular biology and novel therapeutics for IDH mutant gliomas: The new era of IDH inhibitors

Kitagawa, Y., Kobayashi, A., Cahill, D. P., Wakimoto, H., & Tanaka, S. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189102 · Cited by 13

IDH1/2 Mutations in Cancer: Unifying Insights and Unlocking Therapeutic Potential for Chondrosarcoma

Deshmukh, S., Kelly, C. M., & Tinoco, G. (2024) · Targeted Oncology · doi:10.1007/s11523-024-01115-3 · Cited by 15

Cancer modelling in the NGS era – Part I: Emerging technology and initial modelling

Rovigatti, U. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.05.017 · Cited by 13

Accumulation of Multipotent Hematopoietic Progenitors in Peripheral Lymphoid Organs of Mice Over-expressing Interleukin-7 and Flt3-Ligand

Klein, F., von Muenchow, L., Capoferri, G., Heiler, S., Servera, L. A., Rolink, H., Engdahl, C., Rolink, M., Mitrovic, M., Cvijetic, G., et al. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02258 · Cited by 14

Emerging drug profile: Krebs cycle and cancer: IDH mutations and therapeutic implications

Lee, S. M., Urman, A. R., & Desai, P. M. (2019) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2019.1602260 · Cited by 13

I-8, a novel inhibitor of mutant IDH1, inhibits cancer progression in vitro and in vivo

Jia, P., Wu, Y., Du, H., Yang, L., Zhang, Z., Ma, T., Sun, L., Yuan, S., Lu, L., & Zha, X. (2019) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2019.105072 · Cited by 13

IDH1 Associated with Neuronal Apoptosis in Adult Rats Brain Following Intracerebral Hemorrhage

Chen, X., Wang, H., Yu, W., Chen, F., Wang, G., Shi, J., & Zhou, C. (2016) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-016-0421-9 · Cited by 13

Silent Sentence Completion Shows Superiority Localizing Wernicke’s Area and Activation Patterns of Distinct Language Paradigms Correlate with Genomics: Prospective Study

Salek, K. E., Hassan, I. S. A., Kotrotsou, A., Abrol, S., Faro, S. H., Mohamed, F. B., Zinn, P. O., Wei, W., Li, N., Kumar, A. J., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-11192-2 · Cited by 13

Assessment of the Association between Isocitrate Dehydrogenase 1 Mutation and Mortality Risk of Glioblastoma Patients

Dai, Y., Ning, X., Han, G., & Li, W. (2015) · Molecular Neurobiology · doi:10.1007/s12035-015-9104-7 · Cited by 13

Mutations in epigenetic modifiers in acute myeloid leukemia and their clinical utility

Hou, H., & Tien, H. (2016) · Expert Review of Hematology · doi:10.1586/17474086.2016.1144469 · Cited by 13

Modeling myeloproliferative neoplasms: From mutations to mouse models and back again

Morotti, A., Rocca, S., Carrà, G., Saglio, G. N., & Brancaccio, M. (2016) · Blood Reviews · doi:10.1016/j.blre.2016.11.004 · Cited by 13

Leukemic Transformation of Myeloproliferative Neoplasms: Therapeutic and Genomic Considerations

Li, B., Mascarenhas, J. O., & Rampal, R. K. (2018) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-018-0491-5 · Cited by 13

Modeling Normal and Disordered Human Hematopoiesis

Beer, P. A., & Eaves, C. J. (2015) · Trends in cancer · doi:10.1016/j.trecan.2015.09.002 · Cited by 15

Functional requirement of a wild-type allele for mutant IDH1 to suppress anchorage-independent growth through redox homeostasis

Tiburcio, P. D. B., Xiao, B., Berg, S., Asper, S., Lyne, S. B., Zhang, Y., Zhu, X., Yan, H., & Huang, L. E. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1800-0 · Cited by 12

Mutant Idh2 Cooperates with a NUP98-HOXD13 Fusion to Induce Early Immature Thymocyte Precursor ALL

Goldberg, L., Negi, V., Chung, Y. J., Onozawa, M., Zhu, Y. J., Walker, R. L., Pierce, R. M., Patel, D. P., Krausz, K. W., Gonzalez, F. J., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-1027 · Cited by 12

Antiproliferative effect of the histone demethylase inhibitor GSK‐J4 in chondrosarcomas

Lhuissier, E., Aury‐Landas, J., Allas, L., Boittin, M., Boumédiene, K., & Baugé, C. (2019) · IUBMB Life · doi:10.1002/iub.2110 · Cited by 14

Integration and Intersection of Cancer Metabolism with Epigenetic Pathways in Gliomas

Natarajan, S. K., Pun, M. J., Haggerty-Skeans, J., & Venneti, S. (2025) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-111523-023424 · Cited by 13

ZFTA–RELA ependymomas make itaconate to epigenetically drive fusion expression

Natarajan, S. K., Lum, J., Skeans, J. H., Nenwani, M., Eyunni, S., Mota, M., Bayliss, J. M., Deogharkar, A., Hamanishi, E. T., Pun, M. J., et al. (2026) · Nature · doi:10.1038/s41586-025-10005-1 · Cited by 11

The curious case of IDH mutant acute myeloid leukaemia: biochemistry and therapeutic approaches

Gruber, E., & Kats, L. M. (2023) · Biochemical Society Transactions · doi:10.1042/bst20230017 · Cited by 11

IDH1 Mutations Disrupt Blood, Brain, and Barriers

Shih, A. H., & Levine, R. L. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.08.022 · Cited by 11

Registered report: IDH mutation impairs histone demethylation and results in a block to cell differentiation

Richarson, A. D., Scott, D. A., Zagnitko, O. P., Aza‐Blanc, P., Chang, C., Russler‐Germain, D. A., & Reproducibility Project: Cancer Biology (2016) · eLife · doi:10.7554/elife.10860 · Cited by 11

The Burgeoning World of Immunometabolites: Th17 Cells Take Center Stage

Bantug, G. R., & Hess, C. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.09.014 · Cited by 11

Characterization of IDH1 p.R132H Mutant Clones Using Mutation-specific Antibody in Myeloid Neoplasms

Kurt, H., Bueso-Ramos, C., Khoury, J. D., Routbort, M. J., Kanagal‐Shamanna, R., Patel, U., Jorgensen, J. L., Wang, S. A., Ravandi, F., Dinardo, C. D., et al. (2017) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000970 · Cited by 11

Isocitrate dehydrogenase mutations: new opportunities for translational research

Keum, Y., & Choi, B. Y. (2015) · BMB Reports · doi:10.5483/bmbrep.2015.48.5.021 · Cited by 11

Epigenetic Reprogramming in Cancer

Lindroth, A. M., Park, Y. J., & Plass, C. (2014) · Epigenetics and human health · doi:10.1007/978-3-642-31974-7_9 · Cited by 12

HDAC6 deacetylates IDH1 to promote the homeostasis of hematopoietic stem and progenitor cells

Yang, J., Liu, Y., Yin, H., Xie, S., Zhang, L., Dong, X., Ni, H., Bu, W., Ma, H., Liu, P., et al. (2023) · EMBO Reports · doi:10.15252/embr.202256009 · Cited by 10

Transgenerational Epigenetic DNA Methylation Editing and Human Disease

Tompkins, J. D. (2023) · Biomolecules · doi:10.3390/biom13121684 · Cited by 13

3‐(7‐Azaindolyl)‐4‐indolylmaleimides as a novel class of mutant isocitrate dehydrogenase‐1 inhibitors: Design, synthesis, and biological evaluation

Hu, Y., Gao, A., Liao, H., Zhang, M., Xu, G., Gao, L., Xu, L., Zhou, Y., Gao, J., Ye, Q., et al. (2018) · Archiv der Pharmazie · doi:10.1002/ardp.201800039 · Cited by 10

DDIT3 regulates cementoblast mineralization by isocitrate dehydrogenase 1 through nuclear factor‐κB pathway

Liu, X., Sun, H., Yu, M., Liu, J., Yang, B., Wu, Y., & Wang, J. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27811 · Cited by 10

Bioinformatics Analysis of Metabolomics Data Unveils Association of Metabolic Signatures with Methylation in Breast Cancer

Alakwaa, F., & Savelieff, M. G. (2019) · Journal of Proteome Research · doi:10.1021/acs.jproteome.9b00755 · Cited by 10

Beyond Isocitrate Dehydrogenase Mutations: Emerging Mechanisms for the Accumulation of the Oncometabolite 2-Hydroxyglutarate

Peng, S., Chen, H., Chen, L., Yang, G., Liu, J., Cheng, X., & Tang, Y. (2022) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.1c00254 · Cited by 10

Epigenetic maintenance strategies after allogeneic stem cell transplantation in acute myeloid leukemia

Yan, Y., Upadhyaya, R., Zhang, V. W., & Berg, T. (2022) · Experimental Hematology · doi:10.1016/j.exphem.2022.03.003 · Cited by 11

Differentiation therapy for IDH1/2 mutant malignancies

Garrett-Bakelman, F. E., & Melnick, A. M. (2013) · Cell Research · doi:10.1038/cr.2013.73 · Cited by 10

The Potential Equivalents of TET2 Mutations

Paşca, S., Jurj, A. M., Zdrenghea, M., & Tomuleasa, C. (2021) · Cancers · doi:10.3390/cancers13071499 · Cited by 10

Lessons from mouse models of MPN

Benlabiod, C., Dagher, T., Marty, C., & Villeval, J. (2021) · International review of cytology · doi:10.1016/bs.ircmb.2021.02.009 · Cited by 13

Emerging DNA Methylome Targets in FLT3-ITD-Positive Acute Myeloid Leukemia: Combination Therapy with Clinically Approved FLT3 Inhibitors

Tecik, M., & Adan, A. (2024) · Current Treatment Options in Oncology · doi:10.1007/s11864-024-01202-7 · Cited by 9

Metabolic Reprogramming and Adaption in Breast Cancer Progression and Metastasis

Zuo, Q., & Kang, Y. (2025) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-70875-6_17 · Cited by 9

IDH Mutant Cholangiocarcinoma: Pathogenesis, Management, and Future Therapies

Bray, A., & Sahai, V. (2025) · Current Oncology · doi:10.3390/curroncol32010044 · Cited by 9

Targeted Therapies in the Treatment of Adult Acute Myeloid Leukemias: Current Status and Future Perspectives

Castelli, G., Pelosi, E., & Testa, U. (2016) · International Journal of Hematologic Oncology · doi:10.2217/ijh-2016-0011 · Cited by 9

Differential regulation of CpG island methylation within divergent and unidirectional promoters in colorectal cancer

Namba, S., Sato, K., Kojima, S., Ueno, T., Yamamoto, Y., Tanaka, Y., Inoue, S., Nagae, G., Iinuma, H., Hazama, S., et al. (2019) · Cancer Science · doi:10.1111/cas.13937 · Cited by 9

Additional mutations in IDH1/2‐mutated patients with acute myeloid leukemia

Lu, J., Chen, M., Hua, H., Qin, W., Zhang, R., Lu, X., & Chao, H. (2021) · International Journal of Laboratory Hematology · doi:10.1111/ijlh.13648 · Cited by 9

Adapting the drivers to the road: a new strategy for cancer evolution?

Touat, M., Dhermain, F. G., André, F., & Sanson, M. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv137 · Cited by 11

HIF-α factors as potential therapeutic targets in leukemia

Magliulo, D., & Bernardi, R. (2018) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2018.1538357 · Cited by 9

IDH1R132H is intrinsically tumor-suppressive but functionally attenuated by the glutamate-rich cerebral environment

Tiburcio, P. D. B., Xiao, B., Chai, Y., Asper, S., Tripp, S. R., Gillespie, D. L., Jensen, R. L., & Huang, E. L. (2018) · Oncotarget · doi:10.18632/oncotarget.26203 · Cited by 9

Vascular-endothelial response to IDH1 mutant fibrosarcoma secretome and metabolite: implications on cancer microenvironment.

Mao, M., & Leonardi, D. (2019) · Europe PMC (PubMed Central) · Cited by 9

A vaccine for glioma

Agnihotri, S., Yang, K., Mitchell, D. A., & Rich, J. N. (2021) · Nature Cancer · doi:10.1038/s43018-021-00228-2 · Cited by 9

Guanine nucleotide biosynthesis blockade impairs MLL complex formation and sensitizes leukemias to menin inhibition

Shi, X. E., Li, M., Liu, Z., Tiessen, J., Li, Y., Zhou, J., Zhu, Y., Mahesula, S., Qing, D., Tan, L., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-57544-9 · Cited by 9

Epigenetic deregulation in myeloid malignancies

Meldi, K. M., & Figueroa, M. E. (2014) · Translational research · doi:10.1016/j.trsl.2014.04.012 · Cited by 9

S122: MUTANT IDH1 HIJACKS DIFFERENTIATION PROGRAMS IN MYELOID PROGENITOR CELLS TO IMPAIR GRANULOCYTIC DIFFERENTIATION.

Hakobyan, M., Langstein, J., Kleinert, E., Schönung, M., Hartmann, M., Rohdjess, H., Staeble, S., Claus, R., Bullinger, L., Oakes, C. C., et al. (2023) · HemaSphere · doi:10.1097/01.hs9.0000967400.33954.24

Mutated IDH1 Has 2-Hydroxyglutarate-Independent Functions in Leukemogenesis

Chaturvedi, A., Cruz, M. M. A., Jyotsana, N., Sharma, A. K., Yun, H., Görlich, K., Wichmann, M., Schwarzer, A., Preller, M., Thol, F. R., et al. (2012) · Blood · doi:10.1182/blood.v120.21.770.770

Mutant Idh1 Blocks Neutrophil Maturation By Repressing Myeloid Progenitor Programs

Hakobyan, M., Langstein, J., Kleinert, E., Schönung, M., Hartmann, M., Rohdjess, H., Wojtarowicz, J., Staeble, S., Claus, R., Bullinger, L., et al. (2024) · Blood · doi:10.1182/blood-2024-210352

Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations

Gross, S., Cairns, R. A., Minden, M. D., Driggers, E. M., Bittinger, M. A., Jang, H. G., Sasaki, M., Jin, S., Schenkein, D. P., Su, S. M., et al. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20092506 · Cited by 736

Abstract 5452: Cancer-associated metabolite 2-hydroxyglutarate accumulates in AML with IDH1/2 mutations

Fantin, V. R., Größ, S., Cairns, R. A., Minden, M. D., Driggers, E. M., Jang, H. G., Sasaki, M., Jin, S., Schenkein, D. P., Su, S.-S. M., et al. (2010) · Cancer Research · doi:10.1158/1538-7445.am10-5452 · Cited by 1